Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Targacept’s AstraZeneca Deal Down, Not Out

This article was originally published in The Pink Sheet Daily

Executive Summary

First Alzheimer’s Phase III results are not great, but partner wants to see more before deciding.
Advertisement

Related Content

Targacept’s Alzheimer’s Bid With AstraZeneca Is Iffy, But NNR Could Lure Other Suitors
Whatever Works – Or Might: Pfizer/Wyeth May Keep Both Alzheimer’s Bets
Whatever Works – Or Might: Pfizer/Wyeth Likely To Keep Both Alzheimer’s Bets
Tarnished HALO For Targacept/AstraZeneca Schizophrenia Drug
AstraZeneca’s Oral Anticoagulant AZD0837 Phase III Program Pushed Back To 2009
Pfizer Finds Backup For Aricept In Medivation’s Dimebon
Myriad Weighs Strategic Alternatives
Wyeth’s Pipeline Star Bapineuzumab Looks More Long Shot Than Sure Bet
AstraZeneca Licenses Nicotinic Alzheimer’s Treatment From Targacept
AstraZeneca Licenses Nicotinic Alzheimer’s Treatment From Targacept

Topics

Advertisement
UsernamePublicRestriction

Register

PS068353

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel